Literature DB >> 6749531

Comparison of the potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetised dog.

P Lumley, P P Humphrey, I Kennedy, R A Coleman.   

Abstract

Following close intra-arterial administration to the carotid and femoral arterial beds of the anaesthetised dog the rank order of potency for producing vasodilation was PGE greater than 11-deoxy PGE0 greater than PGA greater than PGI2 greater than PGB with the 1- and 2-series prostaglandins equipotent. PGI2 was about 60 times weaker than PGE1. In the mesenteric arterial bed the rank order of potency for producing vasodilation was the same except PGI2 was about equipotent with PGE1. The absolute potency of the prostaglandins, with the exception of PGI, was similar on all three vascular beds. A similar differential action of PGI2 relative to PGE1 was also observed following both left intraventricular and intravenous administration. We suggest that all three arterial beds contain PGE-receptors mediating vasodilatation at which the E-series prostaglandins are potent and PGI2 is weak. In addition the mesenteric bed contains PGI2-receptors which are absent or sparse in the carotid and femoral beds.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749531     DOI: 10.1016/0014-2999(82)90107-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues.

Authors:  Y J Dong; R L Jones; N H Wilson
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

2.  The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.

Authors:  H Giles; P Leff; M L Bolofo; M G Kelly; A D Robertson
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

3.  BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.

Authors:  K A Maubach; R J Davis; D E Clark; G Fenton; P M Lockey; K L Clark; A W Oxford; R M Hagan; C Routledge; R A Coleman
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.